Ryan Cox outlines the recent efforts of his previous employer, Highmark BCBS, and their creation of the Highmark Cancer Collective to promote evidence-based treatment pathways.
Access Experience Team member Dan Danielson documents the launch of Premera’s Value-Based Formulary (VBRx), and the development of its nontraditional tiers for defining and demonstrating value.
Larry Blandford outlines some of the key challenges payers face in relying upon value assessments, and urges greater use of structured methodologies and ongoing assessment.
AET’s Jeremy Schafer provides an overview and essential takeaways from the recent Pharmaceutical Care Management Association (PCMA) meeting, where the focus was on evolving from volume to value.
Defining and measuring value in healthcare has been a focus for both payers and manufacturers for a number of years, and this theme continued during the 2019 AMCP Annual Meeting. Ami Gopalan provides details on several high-profile sessions examining cooperation between providers, payers, and manufacturers to support optimal formulary management and deliver better patient care.